EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Lipogenesis and MASLD: re-thinking the role of SREBPs

Hayato Nakagawa

Archives of Toxicology · 2025

DOI: 10.1007/s00204-025-04052-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Archives of Toxicology, 2025. Verfasst von Hayato Nakagawa. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. nakagawah@med.mie-u.ac.jp. Hauptthemen laut MEDLINE: Lipogenesis, Sterol Regulatory Element Binding Proteins, Fatty Liver. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 93 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Princess Takamatsu Cancer Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and a major risk factor for hepatocellular carcinoma (HCC). Lipid metabolism, particularly de novo lipogenesis (DNL) regulated by sterol regulatory element-binding proteins (SREBPs), plays a key role in MASLD progression. While excessive SREBP activation contributes to hepatic steatosis, our recent findings indicate that strong SREBP inhibition paradoxically exacerbates liver injury and accelerates carcinogenesis in murine MASLD models. Mechanistically, SREBP dysfunction disrupts phospholipid homeostasis, leading to impaired endoplasmic reticulum (ER) membrane fluidity, ER stress, and hepatocyte injury. Transcriptomic analysis of clinical samples revealed a dynamic shift in SREBP activity, with upregulation in early MASLD but significant downregulation in advanced, burned-out MASH. This suggests that SREBP dysfunction in advanced disease may contribute to fibrosis progression and increased HCC risk. Given these findings, therapeutic strategies targeting lipid metabolism in MASLD must be carefully tailored to disease stage. This review provides an updated perspective on the biphasic role of SREBP in MASLD, emphasizing the need to re-think lipid metabolism-targeted therapies and develop personalized interventions to mitigate disease progression and HCC development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LipogenesisSterol Regulatory Element Binding ProteinsFatty LiverHumansAnimalsCarcinoma, HepatocellularLiver NeoplasmsLipid MetabolismDisease Progression

Stichwörter der Autor:innen

Endoplasmic Reticulum (ER) StressHepatocellular Carcinoma (HCC)Lipid metabolismMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Phospholipid HomeostasisSterol Regulatory Element-Binding Protein (SREBP)

Substanzen

Sterol Regulatory Element Binding Proteins

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. nakagawah@med.mie-u.ac.jp.

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Princess Takamatsu Cancer Research Fund
  • Daiichi-Sankyo
  • G7 scholarship foundation
  • Takeda Science Foundation

Zitieren

APA

Nakagawa, H. (2025). Lipogenesis and MASLD: re-thinking the role of SREBPs. Archives of Toxicology. https://doi.org/10.1007/s00204-025-04052-w

Vancouver

Nakagawa H. Lipogenesis and MASLD: re-thinking the role of SREBPs. Archives of Toxicology. 2025. doi:10.1007/s00204-025-04052-w

BibTeX
@article{Nakagawa2025,
  author = {Nakagawa, Hayato},
  title = {Lipogenesis and MASLD: re-thinking the role of SREBPs},
  journal = {Archives of Toxicology},
  year = {2025},
  doi = {10.1007/s00204-025-04052-w}
}
Kostenlos starten →